Technology
Health
Biotechnology

Immune Design

$5.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.17%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Immune Design and other stocks, options, ETFs, and crypto commission-free!

About

Immune Design Corp. Common Stock, also called Immune Design, is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. Read More It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.

Employees
50
Headquarters
Seattle, Washington
Founded
2008
Market Cap
281.55M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
541.59K
High Today
$5.85
Low Today
$5.83
Open Price
$5.83
Volume
101.75K
52 Week High
$5.85
52 Week Low
$1.10

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2014 IPO
US
North America

News

Seeking AlphaFeb 23

Generex: Establishing A Value For Antigen Express' Dividend Shares

On Monday, February 25th, Generex (OTCQB:GNBT) will distribute shares in its subsidiary Antigen Express at a rate of one share for every four shares of Generex to shareholders of record on January 30, 2019. If there are about 60 million Generex shares, that means that there will be 15 million shares outstanding.

87
Guru FocusFeb 21

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp.

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Merck Sharp & Dohme Corp. (NYSE: MRK). Stockholders will receive $5.85 for each share of Immune Design Corp. stock that they hold. The transaction is valued at approximately $300 million and is expected to close in the second quarter of 2019. If you are a stockholder ...

220
Markets InsiderFeb 21

SHAREHOLDER ALERT: WeissLaw LLP Investigates Immune Design Corp.

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Immune Design Corp. ("IMDZ" or the "Company") (NASDAQ: IMDZ) in connection with the proposed acquisition of the Company by Merck & Co., Inc. ("MRK"). Under the terms of the acquisition agreement, shareholders will receive $5.85 in cash for each IMDZ share they own. If you own IMDZ shares and wish to discuss this investigation or have any question...

309

Earnings

-$0.63
-$0.51
-$0.40
-$0.28
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.29 per share
Actual
Expected Mar 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.